Pediatric Oncology Clinical Trials

All Studies
AALL1521 INCB 18424-269 A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Leukemia
AALL1631 International Phase 3 trial in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) testing imatinib in combination with two different cytotoxic chemotherapy backbones
AALL1731 temp close 12/19/2022 A Phase 3 Trial Investigating Blinatumomab (IND# 117467, NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down syndrome BLymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphobl
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk BALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
A Randomized Phase 3 trial of Nivolumab(NSC# 748726 IND# 125462) in Combination with Chemo-immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-cell Lymphoma
All Relapse
A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518, IND#133494) in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)
AALL1821 Groups 1, 2 & 3 Temporary Closure
A Phase 2 Study of Blinatumomab (NSC# 765986, IND# 125462) in Combination with Nivolumab (NSC# 748726, IND# 125462), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/=1 to <31 Years Old with First Relapse 
Pediatric Acute Leukemia (PedAL) Screening Trial – Developing New Therapies for Relapsed Leukemias
A phase 3 randomized trial for patients with de novo AML comparing standard therapy including gemtuzumab ozogamicin GO to CPX-351 with GO, and the addition of the FLT3 inhibitor gilteritinib for patients with FLT3 mutations
Stopping Tyrosine Kinase Inhibitors (TKI) to AssessTreatment-Free Remission (TFR) in Pediatric Chronic Myeloid Leukemia - Chronic Phase (CML-CP)
Children's Oncology Group Neuroblastoma Biology Studies
A Phase 3 Study of 131I-Metaiodobenzlguanidine (131I-MIBG) or Crizotinib Added To Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL) (IND# 134379)
ANBL1232 Group B open Groups A2 and C Temporary Closure
Utilizing Response and Biology Based Risk Factors to Guide Therapy in Patients with Non-High Risk Neuroblastoma. A Groupwide Historically Controlled Phase III Study.
ANBL1821 Temporary closure
A Phase 2 Randomized Study of Irinotecan/Temozolomide/Dinutuximab with or without Eflornithine (DFMO) (IND# 141913) in Children with Relapsed, Refractory or Progressive Neuroblastoma
ANBL19P1 Temporary closure 06/27/2022
A Pilot Study of Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination with Irinotecan and Temozolomide in the Post-Consolidation Setting for High-Risk Neuroblastoma
A Phase 2 Study of Reduced Therapy for Newly Diagnosed AverageRisk WNT-Driven Medulloblastoma Patients
A Phase 2 Study of Dabrafenib (NSC# 763760) with Trametinib (NSC# 763093) after Local Irradiation in Newly-Diagnosed BRAFV600-Mutant High-Grade Glioma (HGG) (IND# 145355)
A Phase 3 Randomized Study of Selumetinib (IND # 77782) versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma
A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine versus Selumetinib (NSC# 748727, IND# 77782) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) not associated with BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)
ACNS1931 Stratum 1 Closed
A Phase 3 Study of Selumetinib (NSC# 748727) or Selumetinib in Combination with Vinblastine for Non-NF1, Non-TSC Patients with Recurrent or Progressive Low-Grade Gliomas (LGGs) Lacking BRAFV600E or IDH1 Mutations
A Phase 3 Study of Sodium Thiosulfate for Reduction of CisplatinInduced Ototoxicity in Children with Average-Risk Medulloblastoma and Reduced Therapy in Children with Medulloblastoma with Low-Risk Features
Renal / Germ Cell
Renal Tumors Classification, Biology, and Banking Study
AGCT1531 AVA Hears Temporary Closure 0212/2021
A Phase 3 Study of Active Surveillance for Low risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors
Phase 3 Accelerated BEP Trial: A randomized phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumors
AREN1921  Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)
A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients with Osteosarcoma
AHEP1531 Temporary Closure of Accrual to Group D, effective June 30, 2023
AHEP1531 Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma
S1826 temp closure 10/5/2022
A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
Soft Tissue Sarcoma
A Randomized Phase 3 Trial of Vinorelbine, Dactinomycin, and Cyclophosphamide (VINO-AC) Plus Maintenance Chemotherapy with Vinorelbine and Oral Cyclophosphamide (VINO-CPO) vs Vincristine, Dactinomycin and Cyclophosphamide (VAC) plus VINOCPO Maintenance
A Prospective Phase 3 Study of Patients with Newly Diagnosed Very Low-risk and Low-risk Fusion Negative Rhabdomyosarcoma
Solid Tumor Relapse
APEC1621-Master APEC1621-Master NCI-COG Pediatric Match (Molecular Analysis For Therapy Choice) Master VersionControl Protocol
Hematology Protocols
A phase 2, Multicenter, Open-Label Study to Assess Appropriate Dosing and to Evaluate Safety of Crizanlizumab, with or without Hydroxyurea/Hydroxycarbamide, in Sequential, Descending Age Groups of Pediatric Sickle Cell Disease Patients with VasoOcclusive Crisis
Other Studies
Financial Distress during Treatment for Pediatric Acute Lymphoblastic Leukemia in the United States
Prospective Cohort Study to Evaluate Immunologic Response Following COVID-19 Vaccination in Children, Adolescents and Young Adults with Cancer
Neuropsychological, Social, Emotional, and Behavioral Outcomes in Children with Cancer: A Groupwide Non-Therapeutic Study
Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Research Program (NCORP)
StepByStep: A Randomized Trial of a Mobile Health and Social Media Physical Activity Intervention among Adolescent and Young Adult Childhood Cancer Survivors
The Project: Everychild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study


Her 2 Positive
 NeoAdj/Adj HER2+ pts with Stage II or IIIA The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): CompassHER2 pCR: Preoperative THP and postoperative HP in patients who achieve a pathologic complete response 
 ADJ HER2+ patients with residual disease after preoperative chemotherapy and HER2-directed therapy; >6 cycles pre or pre&post operatively. The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 Compared with T-DM1 and Tucatinib 
 Her 2 Negative
 HR+/HER2- breast cancer after CDK4/6 and aromatase inhibitor treatment. Gedatolisib with fulvestrant or palbociclib. A Phase 3, Open-Label, Randomized, Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-
Care Therapies in Patients with HR-Positive, HER2 Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy
 Adjuvant therapy for ER+ HER2-positive early breast cancer: recruiting high-risk patients; considering those who decline Abemaciclib A Phase III Randomized, Open-Label Multicenter Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared with Physician's Choice if Adjuvant Endocrine Monotherapy in Patients with Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer - Medium risk cohor
closed to accrual. High Risk Cohort Open only
 Triple Negative
 Three-arm plasma ctDNA-stratified research. Patients with persisting TNBC disease after pre-operative therapy will be randomly assigned to one of three arms based on plasma ctDNA positivity and genomic marker expression (s). A Phase II circulating tumor DNA enriched, genomically directed postneoadjuvant trial for patients with residual triple negative breast cancer (PERSEVERE) -Suspended to Accrual As of 4/6/2023 Due to an updated risk in the new Atezolizumab IB v19, Indiana University is Temporarily Suspending the trial to accrual.
Arm 1a: DNA Repair pathway = talazoparib + capecitabine
Arm 1b: Immunotherapy pathway = atezolizumab + capecitabine
Arm 1c: PI3K Pathway = inavolisib + capecitabine
Arm 1d: DNA Repair + Immunotherapy = talazoparib + atezolizumab + capecitabine
Arm 2: ctDNA positive but no actional target: Capecitabine or MD Choice Arm 3: ctDNA Negative: No Therapy, Capecitabine or MS Choice
 Breast: Radiation
 SRS with Olaparib and immunotherapy for triple-negative or BRCA-mutated breast cancer brain metastases. Phase l/II Stereotactic radiosurgery with DDR inhibitor (Olaparib)
followed by adjuvant durvalumab and chemotherapy in subjects with breast cancer brain metastases (SOLARA) - Temporarily Suspended second
week of May •They accrued the third patient of Dose Level 2, waiting for them to get through their DLT period.
 For pts with low-risk newly diagnosed invasive cancer treated with BCS or mastectomy with clear margins of excision. Patients with T3N0 disease are eligible. CCTG MA.39: A Randomized Trial of Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer
 Oracle: ALL COMERS. Residual disease after completion of neoadjuvant chemotherapy  ORACLE: Observation of REsiduAl Cancer with Liquid biopsy Evaluation
 Gene expression in breast cancer - FAU/MCI - Oncology Biorepository  A Grassroots Initiative to Increase Access to Care - Equitable Imaging and Diagnostics Testing Services (Community Foundation Broward Grant) - OPEN TO ACCRUAL

Adjuvant study for pts with completely resected St. IB- IIIA Non-Squamous NSCLC + adequate tissue for central review  Screening: ALCHEMIST: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial Stage 2A-3B (T3-4N2) Only
 ALK Pts: A Randomized Phase III Trial for Surgically Resected Early Stage NSCLC: Crizotinib vs. Observation for Patients with Tumors Harboring the ALK Fusion Protein
 Integration of immunotherapy into adjuvant therapy for resected NSCLC: ALCHEMIST chemo-IO
Must be EGFR (-) & ALK (-)
 Pts with treatment-naïve unresectable, locally advanced, Stage III NSCLC  Phase 3 Study of Pembrolizumab (MK-3475) in Combination with
Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib vs Concurrent
Chemoradiation Therapy Followed by Durvalumab in Participants with Unresectable, Locally Advanced, Stage
III Non-Small Cell Lung Cancer (NSCLC)
 1st Line NSCLC Non-Squamous or Squamous  A Phase 3, Open-Label, 3-Cohort Randomized Study of N-803 in Combination with Current Standard of Care vs. Standard of Care as First-Line Treatment for Patients with Advances or Metastatic Non-Small Cell Lung Cancer (NSCLC) Enrollment hold (pending development of Protocol Amendment)
 Anti-PD-(L)1 Therapy with NSCLC as First-Line Therapy or Progressing on Single-Agent First-Line Anti-PD-(L)1  A Randomized, Double-Blind, Placebo-Controlled Trial of Tomivosertib in Combination with Anti-PD-(L)1 Therapy in Subjects with NSCLC as First-Line Therapy or
When Progressing on Single-Agent First-Line Anti-PD- (L)1. Cohort B open only
 2nd+ Line mets. NSCLC - Screening Protocol (pts. Can be screened at or before progression  A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer
 2nd+ Line mets. NSCLC - Screening Protocol (pts. Can be screened at or before progression  S1900E - AMG 510 (KRAS G12C Mutated)
S1800D - ALT 803 (Stage IV or Recurrent/Previously treated Anti-PD-1 or Anti-PD-L1) closed 03/10/2023
S1900F - Carboplatin/Pemetrexed w/wo Selpercatinib (Non-Squamous RET Fusion-Positive Stage IV)
 Pleural effusion  Prospective Randomized Trial of Intrapleural Fibrinolytic Therapy to Enhance Chemical Pleurodesis
 Metastic NSCLC & EGFR Mutation  A Randomized, Three-Arm, Open-Label Phase 3b Clinical Trial of Aumolertinib, versus Aumolertinib with
Chemotherapy, versus Osimertinib for Patients with Metastic NSCLC and an EGFR Mutation
 Pts with New ≤ 30 mm benign pulmonary nodules.Full- transcriptome RNA sequencing test (Percepta Nasal Swab)  NIGHTINGALE: Clinical Utility of Management of Patients with CT and LDCT Identified Pulmonary Nodules Using the Percepta Nasal Swab Classifier
 Advanced Non-Small Cell Lung Cancer with a KRAS Mutation  A Phase 1 Study of the SHP2 Inhibitor bbp-3398 (formerly known as IACS-15509) in combination with the Programmed Death Receptor-1 Blocking Antibody Nivolumab in Patients with Advanced Non-Small Cell Lung Cancer with a KRAS Mutation.
SIV 04/17/2023 pending activation

Gastrointestinal (GI)
 Pancreatic Cancer Screening Registry  A Registry for Pancreatic Cancer Screening in Patients with Known Genetic Mutations or Familial History
 CRC- Adj
Resected stage IIA rand to Tx vs. Surveillance using LUNAR assay
 Phase II/III Study of Circulating tumor DNA as a Predictive BiomaRker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA)
Basket Trials
Oral VMD-928; advanced solid tumors or lymphoma. TrkA protein overexpression, NTRK1 gene fusion, or NTRK1 mutation-related tumor progression after pan- Trk inhibitor treatment.  An Open-Label, Multiple-Dose, Dose-Escalation Study to
Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of VMD-928 in Subjects with Solid Tumors or Lymphoma
 1st+ Line for pts wit loc. adv/mets solid tumors with ROS1, NTRK1/2/3 rearrangements. Prior chemo/IO allowed  A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and
Anti-Tumor Activity of TPX-0005 in Patients with Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-
3 Rearrangements
Enrollment will close for all ROS1 Cohorts (EXP-1, -2, -3,
and -4). Acceptance of EXP-5 and EXP-6 NTRK Cohorts will continue
 For patients with locally adv/mets. RET fusion +ve solid tumors that have progressed on standard tx. or no standard tx. exists  A Phase 1/2 Study of Oral LOXO-292 in Patients with Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors with RET Activation (LIBRETTO-001) Open Cohorts: 1, 2, & 5 (RET fusion-positive solid tumors other than NSCLC or Thyroid)
 Advanced Solid Tumors with KRAS p.G12C mutation  A Phase 1b, Master Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510
in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation
 Oracle: ALL COMERS. Residual disease after completion of neoadjuvant chemotherapy  ORACLE: Observation of REsiduAl Cancer with Liquid biopsy Evaluation
 Advanced Solid Tumors with ROR 2 expression  A Phase 1/2 Dose Escalation and Dose Expansion Study of BA3021 Alone and in Combination with Nivolumab in
Patients with Advanced Solid Tumors
 IgG1 monoclonal antibody (anti-CTLA4) TNBC, Pancreas, Melanoma, H&N, Ovarian, and other advanced solid tumors with detectable disease and no SOC alternatives Safety, Pharmacokinetics (PK), and Efficacy of ONC-392
as a Single Agent and in Combination with Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open-label Phase IA/IB Study 
 Advanced or metastatic NSCLC and other solid tumors.
ROS1 fusion-positive
 A Single-Arm, Open-Label, Multicenter Phase 2 Study to
Evaluate the Efficacy and Safety of Taletrectinib in Patients with Advanced or Metastatic ROS1 Positive NSCLC and Other Solid Tumors. ROS1 TKI treatment naïve, or treated with prior ROS1 TKI(s)Temporary closure of Cohort 3
 HBI-8000 30 mg oral BIW and/or nivolumab IV.
Metastatic melanoma patients
 Phase 3 study to compare the efficacy and safety of HBI-
8000 or Placebo combined with nivolumab on patients with unresectable or metastatic melanoma - Open Label Cohort for adult subjects with brain metastases is
 Advanced Solid Tumors with a KRAS G12C mutation  Expanded access use of MRTX849 for the treatment of patients with advanced solid tumors with a Kras G12C mutation
 Lung, melanoma, and colorectal cancer patients who receive SOC IO and SIGNATERA testing  BESPOKE Study of ctDNA Guided Immunotherapy - Enrollment On Hold as of 06APR2023
 Pts with metastatic NSCLC or metastatic cutaneous melanoma  A Phase 2 Study of Brentuximab Vedotin in Combination with Pembrolizumab in Subjects with Metastatic Solid Malignancies after progression on prior PD-1 inhibitor Treatment
 Monotherapy and in Combination with Pembrolizumab with Advanced, relapsed or refractory solid tumors  A Phase 1, Open-Label, Multicenter, Dose-Escalation, Dose-Expansion, and Dose-Randomization Study of IO- 108 as Monotherapy and in Combination with Pembrolizumab, in Adult Patients with Advanced Relapsed or Refractory Solid Tumors Pending activation
 SRK-181 (TGFβ1 monoclonal antibody) administered alone and in combination with anti-PD-(L)1 therapy. (NSCLC), (UC), (MEL), (ccRCC) or other advanced or metastatic solid A Phase 1, Open-Label, Dose-Escalation, and Dose- Expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SRK-181 Administered Alone or In Combination with a Checkpoint Inhibitor in Patients with Locally Advanced or Metastatic Solid Tumors (DRAGON) - NEW STUDY 

Hematology (HEME)
 Pts with R/R DLBCL or Car-T Therapy Eligible and transplant ineligible A Phase 1B, Open-Label, Multicenter, Single Arm Study Evaluating The Preliminary Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination with Rituximab plus Ifosfamide, Carboplatin Etoposite Phosphate in Patients with Relapsed/Refractory Transplant or Car-T Therapy Eligible Diffuse B-Cell Lymphoma 
 Epcoritamab for the treatment of R/R DLBCL and R/R FL grade 1, 2, or 3a, with documented CD20+ mature B-cell neoplasm  A Phase 2, Open-Label Trial to Evaluate Safety of Epcoritamab Monotherapy in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma Grade 1-3a When Administered in the Outpatient Setting
 HIV+ patients with Stage II-IV CD20 +/- DLBCL; first-line treatment for dose-finding cohort; limited prior treatment for dose expansion cohort A Pilot Study of Ibrutinib and R-da-EPOCH for Front Line Treatment of AIDSRelated Lymphomas
 2nd Line+ for Patients with Relapsed/Refractory DLBCL  A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Safety and Efficacy of Polatuzuman Vedotin in Combination with Rituximab plus Gemcitabine Plus Oxaliplatin (R-GEMOX) versus R_GEMOX Alone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma
 3rd+ Line for Patients with Relapsed/Refractory CLL  A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody®-CD3 X CD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia Richter's Transformation Cohort is open
 Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) not Eligible for Intensive Induction Chemotherapy”  A Phase 1/2, Multicenter, Open-Label, Randomized, Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients with Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML) not Eligible for Intensive Induction Chemotherapy
 Loncastuximab Tesirine in combination with other anti-cancer treatments for recurrent or refractory B-cell non-Hodgkin lymphoma (DLBCL, HGBCL, FL, MCL, and MZL) (BL)  A Phase 1b Open-Label Study to Evaluate the Safety and Anti-Cancer Activity of Loncastuximab Tesirine in Combination with Other Anti-cancer agents in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS 7)
 Newly diagnosed precursor B-cell ALL A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (A Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) with Newly Diagnosed Precursor B-Cell ALL Temporary Closed to Accrual
 Pts with previously untreated TP53 mutant AML  A Phase 3, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination with Azacitidine versus Physician’s Choice of Venetoclax in Combination with Azacitidine or Intensive Chemotherapy in Previously Untreated Patients with TP53 Mutant Acute Myeloid Leukemia
 Multiple Myeloma
 Elranatamab - Relapsed/Refractory Multiple Myeloma - EAP MAGNETISMM17: Elranatamab Expanded Access Protocol in Adults With Relapsed/Refractory Multiple Myeloma - NEW STUDY
 CIBMTR BMT Registry  Protocol for a Research Database Hematopoietic Stem Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries
 CIBMTR Sample repository Protocol for a Research Sample Repository for Allogeneic Hematopoietic Stem Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries
 Connect MDS/AML Registry  The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry  AML, HR-MDS and ICUS cohorts are CLOSED